Skip to content

Released Nov 15, 2021, before the open

10-Q filed Nov 15, 2021, 46 days after period end · 0001193125-21-329068

Q3 2021 · 10-Q
Revenue—
Net Income-$3.90MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.10N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$3,935,000N/M
Operating Cash Flowderived-$7,688,000N/M
Free Cash Flowderived-$7,696,000—

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020
Net Income-$3.90M-$2.49M
EPS Diluted-$0.10-$5.94

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR